RecruitingNCT07041125
Concomitant LAAC/AF Ablation (Watchman FLX Pro)
Ablation With FARAPULSE and Left Atrial Appendage Closure With Watchman for Integrated Management of Atrial Fibrillation)
Sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Enrollment
120 participants
Start Date
Jun 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This sub-study is a prospective/retrospective, non-randomized, observational, comparative cohorts study, embedded in and expanding on the infrastructure of a real-world AF ablation registry DISRUPT-AF (NCT06335082).
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patients who are determined by physicians to be eligible for LAAC
- Patients whose LAAC with Watchman FLX Pro procedures are performed concomitant following AF ablation procedure
- Willing and able to provide additional informed consent to the sub-study (unless waiver of consent is obtained)
Exclusion Criteria1
- Patients who are participating in other DISRUPT-AF sub-studies
Interventions
DEVICEWatchman FLX™ Pro device.
Patients eligible for the main DISRUPT-AF Registry with a planned concomitant LAAC procedure using the Watchman FLX™ Pro device.
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07041125